• Radiation Therapy
    • K Kian Ang
    • K Kian Ang: Influence Statistics

      K Kian Ang

      K Kian Ang

      Show email address

      University of Texas-MD Anderson Cancer Center, Houston, Texas | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      K Kian Ang:Expert Impact

      Concepts for whichK Kian Anghas direct influence:Radiation therapy,Spinal cord,Head neck,Neck cancer,Squamous cell,Radiation therapy oncology,Neck neoplasms humans,Cell carcinoma.

      K Kian Ang:KOL impact

      Concepts related to the work of other authors for whichfor which K Kian Ang has influence:Squamous cell,Neck cancer,Radiation therapy,Nasopharyngeal carcinoma,Human papillomavirus,Oral cavity,Local control.

      KOL Resume for K Kian Ang


      University of Texas-MD Anderson Cancer Center, Houston, Texas

      MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.


      David I. Rosenthal, Diana Bell, and Kian K. Ang, The University of Texas MD Anderson Cancer Center, Houston, TX; Paul M. Harari, University of Wisconsin, Madison, WI; Jordi Giralt, Hospital Vall d'Hebron, Barcelona, Spain; David Raben, University of Colorado School of Medicine, Aurora, CO; Joyce Liu, Merck Serono, Beijing, People's Republic of China; Jeltje Schulten, Merck KGaA, Darmstadt, Germany; and James A. Bonner, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

      The University of Texas MD Anderson Cancer Center Department of Radiation Oncology Houston Texas


      MD Anderson Cancer Center, Houston, TX


      University of Texas MD Anderson Cancer Center Houston Texas

      MD Anderson Cancer Center, Houston, TX, USA


      MD Anderson Cancer Center, Houston, Texas

      Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, University of North Carolina Lineberger, Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina

      Emeritus Professor and Consultant, Department of Radiation Oncology, Mayo Clinic College of Medicine and Mayo Clinic, Scottsdale, Arizona


      Authors' Affiliations: Departments of Radiation Oncology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center; Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston; and Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas

      University of Chicago, Chicago, IL

      LDS Hospital, Salt Lake City, UT

      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

      Maimonides Cancer Center, Brooklyn, NY


      University of Texas M.D. Anderson Cancer Center, Houston, TX

      Radiation Oncology Department, MD Anderson Cancer Center, Houston, USA


      Moffitt Cancer Center, Tampa, FL

      Image-Guided Therapy Center

      Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom

      Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

      University of California, San Francisco, San Francisco


      Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Box 97, 1515 Holcombe Blvd., Houston, TX 77030; Fax: 713‐563‐2366.

      Radiation Therapy Oncology Group Headquarters and Statistical Center and the American College of Radiology, Philadelphia, PA

      Maimonides Medical Center, NY

      From the Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University

      Sign-in to see all concepts, it's free!
      Sample of concepts for which K Kian Ang is among the top experts in the world.
      Concept World rank
      hyperfractionated radiotherapy patients #1
      radiation myelopathy volume #1
      major radiation failure #1
      tumor cure radiation #1
      contrast media experience #1
      cerebrovascular risk difference #1
      mouth pain difficulty #1
      patients surgery radiotherapy #1
      tolerability concurrent cisplatin #1
      accelerated regimens #1
      a431 tumor xenografts #1
      factor radiation #1
      cerebrovascular disease risk #1
      metastasis gli1 #1
      neck doses #1
      lrc 003 rates #1
      localregional control stage #1
      hyperfractionation ahfxs #1
      parotid glands 75150 #1
      time repopulation kinetics #1
      cisplatin neck carcinoma #1
      laryngeal cancer intent #1
      intensification radiotherapy schedules #1
      t1–2 glottic cancer #1
      ice response relationship #1
      patients mvd or60 #1
      amifostine igf1 #1
      animals kidney doses #1
      hypopharyngeal dose #1
      fhit expression port #1
      unpartnered females #1
      symptom burden instrument #1
      opscc rtog #1
      community settings 24 #1
      beam path toxicities #1
      125 30 112 #1
      variants advanced head #1
      pretreatment qol survival #1
      therapy improvements expense #1
      hn5 cells nfkappab #1
      response hncs #1
      tumor vascularity radiotherapy #1
      partnered whites #1
      scchn egfr inhibitors #1
      neck local recurrence #1
      effects dental artifacts #1
      pretreatment level apoptosis #1
      c225 antitumor efficacy #1
      radiation igf type #1
      radiosensitization ddr #1
      Sign-in to see all concepts, it's free!

      Prominent publications by K Kian Ang

      KOL-Index: 21017

      BACKGROUND: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival.

      METHODS: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a ...

      Known for Patients Cetuximab | Locoregionally Advanced Head | Antibodies Monoclonal Antibodies | Year Survival | Neck Cancer
      KOL-Index: 18817

      PURPOSE: Surgery is the primary treatment for adenoid cystic carcinomas arising from major and minor salivary glands of the head and neck. However, local recurrence is frequent because of the infiltrative growth pattern and perineural spread associated with these tumors. At UTMDACC, we have had a longstanding policy of using postoperative radiotherapy to reduce the risk of local recurrence and to avoid the need for radical surgery; this 30-year retrospective study analyzes the results of ...

      Known for Positive Margins | Nerve Invasion | Adenoid Cystic | Postoperative Radiotherapy | Neck Surgery
      KOL-Index: 18505

      PURPOSE: The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation and two types of accelerated fractionation individually against standard fractionation.

      METHODS AND MATERIALS: Patients with locally advanced head and neck cancer were randomly assigned to receive radiotherapy delivered with: 1) standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 ...

      Known for Standard Fractionation | Rtog 9003 | Neck Squamous | 5 Week | Female Head
      KOL-Index: 18459

      PURPOSE: We conducted a retrospective evaluation of the IMCL-9815 study to examine the association of human papillomavirus (HPV) and p16 protein expression status with outcomes in patients with oropharyngeal carcinoma (OPC) receiving radiotherapy (RT) plus cetuximab or RT alone.

      PATIENTS AND METHODS: In the IMCL-9815 study, patients were randomly allocated to receive RT plus weekly cetuximab or RT alone. A subpopulation of patients with p16-evaluable OPC was retrospectively evaluated on ...

      Known for Human Papillomavirus | P16 Status | Cetuximab Patients | Phase Iii | Squamous Cell
      KOL-Index: 17297

      PURPOSE: Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.

      EXPERIMENTAL DESIGN: We conducted an integrated gene expression, ...

      Known for Egfr Inhibitor Resistance | Pi3k Inhibitors | Therapeutic Target | Gene Signature | Nsclc Emt
      KOL-Index: 17024

      BACKGROUND: Radiation dermatitis occurs to some degree in most patients receiving radiotherapy, with or without chemotherapy. Patients with squamous cell carcinoma of the head and neck (SCCHN) who receive radiotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, may develop a characteristic acne-like rash in addition to dermatitis.

      DESIGN: An advisory board of 11 experienced radiation oncologists, medical oncologists and dermatologists ...

      Known for Egfr Inhibitors | Radiation Dermatitis | Squamous Cell Carcinoma | Monoclonal Antibodies | Neck Scchn
      KOL-Index: 16500

      BACKGROUND: The gold standard endpoint in randomised trials of locally advanced head and neck squamous-cell carcinoma (HNSCC) is overall survival. Our objective was to study whether duration of locoregional control or event-free survival (EFS) could be considered as surrogate endpoints to estimate the effect of radiotherapy and chemotherapy on overall survival. This would allow a reduction in the duration and cost of the development of new treatments.

      METHODS: Individual patient data ...

      Known for Surrogate Endpoints | Individual Patient Data | Locally Advanced Head | Locoregional Control | Efs Survival
      KOL-Index: 15468

      Epithelial-mesenchymal transition (EMT) is associated with characteristics of breast cancer stem cells, including chemoresistance and radioresistance. However, it is unclear whether EMT itself or specific EMT regulators play causal roles in these properties. Here we identify an EMT-inducing transcription factor, zinc finger E-box binding homeobox 1 (ZEB1), as a regulator of radiosensitivity and DNA damage response. Radioresistant subpopulations of breast cancer cells derived from ...

      Known for Dna Damage | Emt Radioresistance | Ataxia Telangiectasia | Zeb1 Promotes | Protein 1
      KOL-Index: 15390

      BACKGROUND: In the current study the authors assessed the antitumor activity (including response rate, duration of response, and survival) and toxicity profile (including anorexia, fatigue, emesis, and peripheral neuropathy) of a combination of paclitaxel, ifosfamide, and carboplatin (TIC) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial hypothesis was that the TIC therapeutic index would be as high as that of paclitaxel, ...

      Known for Squamous Cell | Metastatic Head | Paclitaxel Ifosfamide | Carboplatin Patients | Median Duration
      KOL-Index: 15201

      PURPOSE: To report results of a randomized phase II trial (Radiation Therapy Oncology Group RTOG-0234) examining concurrent chemoradiotherapy and cetuximab in the postoperative treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with high-risk pathologic features.

      PATIENTS AND METHODS: Eligibility required pathologic stage III to IV SCCHN with gross total resection showing positive margins and/or extracapsular nodal extension and/or two or more nodal ...

      Known for Postoperative Chemoradiotherapy | Squamous Cell | Cetuximab Patients | Head Neck | Cisplatin Arm
      KOL-Index: 15168

      BACKGROUND: Sinonasal neuroendocrine tumors are rare malignancies that are represented by a spectrum of histologies, including esthesioneuroblastoma (ENB), sinonasal undifferentiated carcinoma (SNUC), neuroendocrine carcinoma (NEC), and small cell carcinoma (SmCC). The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment ...

      Known for Enb Patients | Sinonasal Malignancies | Neuroendocrine Differentiation | 5 Years | Undifferentiated Carcinoma
      KOL-Index: 15062

      PURPOSE: In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab.

      PATIENTS AND METHODS: Patients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer ...

      Known for Cetuximab Patients | Life Qol | Monoclonal Antibodies | Locoregional Control | Receptors Head
      KOL-Index: 14720

      PURPOSE: Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS).

      PATIENTS AND METHODS: Eligible patients with stage III or IV HNC were randomly ...

      Known for Neck Carcinoma | Stage Iii | Cisplatin Cetuximab | Pfs Patients | Female Head
      KOL-Index: 14447

      BACKGROUND: This retrospective study assesses the outcomes and patterns of failure in patients with squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site treated with combined surgery and postoperative radiotherapy.

      METHODS: One hundred thirty-six patients with squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary source were treated postoperatively with radiotherapy at the University of Texas M. D. Anderson Cancer Center ...

      Known for Primary Site | Squamous Cell | Carcinoma Metastatic | Postoperative Radiation | Cervical Lymph

      Key People For Radiation Therapy

      Top KOLs in the world
      Carlos A Perez
      radiation therapy uterine cervix tumor control
      James D Cox
      radiation therapy lung cancer small cell
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Walter John Curran
      radiation therapy brain metastases lung cancer
      Ritsuko R Komaki
      lung cancer radiation therapy small cell
      Thomas F Pajak
      radiation therapy neck cancer late effects

      University of Texas-MD Anderson Cancer Center, Houston, Texas | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA | Department of Experimental Radiation Oncology, The University of Texas MD Anderson

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.